



ASX ANNOUNCEMENT

23 February 2024

Cann Group to postpone investor webinar

23 February 2024 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) has postponed the investor webinar, which was announced on 14 February 2024. The webinar was originally scheduled to take place on **Wednesday, 28 February 2024 at 11:00 am** (Melbourne time).

The Company will advise of a revised date for the webinar in due course.

Authorised for release by the Steven Notaro, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine
Corporate Communications Manager
+61 439 492 955
jackson.paine@canngrouponlimited.com

For all other information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Head of Legal & Regulatory Affairs and
Company Secretary
Cann Group Limited
+61 3 9095 7088
steven.notaro@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com